AUS
NZ
UK
CA
USA
IND
Highlights
Varoglutamstat exhibits promising impact on kidney function in combination with SGLT-2 inhibitors
U.S. composition of matter patent granted, extending IP protection into next decade
Preparations continue for Phase 2b clinical trial in diabetic kidney disease
Vivoryon Therapeutics N.V. (LON:VVY), listed on the FTSE AIM UK 50 INDEX, operates within the biopharmaceutical sector, focusing on inflammatory and fibrotic conditions with a strong emphasis on kidney-related disorders. The company recently reported its operational progress and financial results for the first quarter of the year, highlighting the development of its lead compound, varoglutamstat.
Varoglutamstat Development in Kidney Disease
Vivoryon has continued to prioritize varoglutamstat, a small molecule therapeutic, for addressing kidney-related complications. The company is preparing for a Phase 2b clinical study targeting diabetic kidney disease, following encouraging data observed in earlier studies. A key aspect of this advancement is the demonstration of varoglutamstat’s clinical effect on estimated glomerular filtration rate (eGFR), a central marker of kidney function.
Preclinical assessments further indicate that varoglutamstat, when used alongside an SGLT-2 inhibitor, shows enhanced therapeutic outcomes under various treatment scenarios. These findings are shaping the framework for combination-based regimens in future trials.
Meta-Analysis Supports Long-Term Impact
Vivoryon disclosed findings from a meta-analysis combining data from its VIVIAD and VIVA-MIND trials. This analysis revealed consistent and sustained improvement in eGFR across the studied population, with a more notable effect observed among participants with diabetes. The meta-analysis strengthens the clinical narrative for varoglutamstat, affirming its reproducibility and reliability in independent datasets.
The results were presented during the ERA 2025 Congress held in Vienna, further underlining the importance of these findings within the nephrology research community.
Intellectual Property Strengthened in U.S.
A significant milestone for the company includes the granting of a new composition of matter patent for varoglutamstat in the United States. The expedited review process culminated in an approval that extends the protection of this compound through the next two decades. This strategic enhancement of the company’s intellectual property portfolio supports long-term clinical and commercial planning.
The newly secured patent rights are expected to underpin Vivoryon’s expansion into markets where robust protection is essential for proprietary therapeutics, especially in chronic disease areas like kidney disorders.
Conference Call to Discuss Forward Developments
Company leadership will be addressing the developments in more detail during a scheduled conference call. The management team aims to discuss clinical and strategic goals for the next stages in varoglutamstat’s development path, with emphasis on diabetic kidney disease and further applications within nephrology.
Vivoryon continues to operate with a focus on scientific rigor, leveraging its portfolio to develop therapeutic strategies that align with unmet clinical needs in the kidney disease space. The combination of clinical advancement, data consolidation, and regulatory success reflects the company’s trajectory within the FTSE AIM 100 Index landscape.
